Loading
Compass Therapeutics, Inc. Stock: price and insider trades · United States
1 insider bought €19k of shares over the last 90 days, the latest filed 02 Oct 2026.
Compass Therapeutics, Inc.: what insiders have been doing
Compass Therapeutics, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). Over the twelve months to 18 October 2026, 11 filings were filed, from 4 insiders.
Not one open-market sale was filed. On the buying side, 1 insider reported 2 purchases totalling €19k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. One trade stands out by size: a purchase of €16k from Lerner Neil, disclosed on 2 October 2026, or 0.0092% of market capitalisation. Among those who bought: 1 finance chief.
Compared with its exchange (5,808 companies, median 19 filings), a count of 11 filings is below the norm. The full history, which starts in 2021, counts 30 purchases against 3 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists net income at -66.5 m USD.
The last insider purchase was made public on 2 October 2026, 16 days ago. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. For comparison, the SEC allows two business days to file a Form 4.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Cytosorbents Corp also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
61
Thresholds
n/a
Buy Volume
€8M
30 ops. · all time
Sell Volume
€5M
3 ops. · all time
Who traded when
BuySaleNeil Lerner4 buys
Jonathan Anderman2 buys
Carl L. Gordon1 sale
Orbimed Advisors LLC1 sale
Thomas J. Schuetz1 buy
Since the insiders bought
- +14.8%Entry US$2.10 · Close at T+365 US$2.41
- +211.4%Entry US$1.75 · Close at T+365 US$5.45
- +211.4%Entry US$1.75 · Close at T+365 US$5.45
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.86
Analyst consensus
11 analysts1.53/5
US$1.00Target US$5.45(+536%)US$12.00
Income statement
EBITDA-US$71.4M
Net income-US$66.5M0.0% margin
Valuation
PER (forward)-1.6x
P/Book0.9x
Beta0.91
Balance sheet & cash
Market capUS$154.3M
Total debtUS$9.8M
Free Cash Flow-US$49.2M
Debt / Equity6%
Profitability & ownership
ROE-56.7%
ROA-33.0%
% insiders12.5%
% institutions88.5%
Last declaration on 2 October 2026
Declarations61 total
20,000 shares@ US$0.920.0092% mcap4.7% of flowCommon StockSEC:0001171843-26-006349:0
Canonical exit: 30 Dec 2026 (T+90)
2,500 shares@ US$1.140.0014% mcap0.8% of flowCommon StockSEC:0001171843-26-006235:0
Canonical exit: 23 Dec 2026 (T+90)
15,000 shares@ US$1.890.0080% mcap7.4% of flowCommon StockSEC:0001171843-26-002834:0
25,000 shares@ US$1.890.013% mcap5.5% of flowCommon StockSEC:0001171843-26-002840:0
36,687 shares@ US$6.524.7% of flowCommon StockSEC:0001171843-26-000722:0
46,777 shares@ US$5.355.0% of flowCommon StockSEC:0001171843-26-000205:0
125,000 shares@ US$5.1746.8% of flowCommon StockSEC:0001171843-26-000062:0
250,000 shares@ US$5.1725.5% of flowCommon StockSEC:0001171843-26-000060:0
62,500 shares@ US$5.1783.9% of flowCommon StockSEC:0001171843-26-000056:0
150,000 shares@ US$5.1790.6% of flowCommon StockSEC:0001171843-26-000051:0
44,025 shares@ US$4.834.2% of flowCommon StockSEC:0001171843-25-007400:0
10,000 shares@ US$2.110.4% of flowCommon StockSEC:0001171843-25-003462:0
Canonical exit: 25 Aug 2025 (T+90)
3,571,428 shares@ US$1.5943.3% of flowCommon StockSEC:0000947871-25-000384:0
3,571,428 shares@ US$1.5943.3% of flowCommon StockSEC:0000947871-25-000385:0
20,000 shares@ US$1.543.9% of flowCommon StockSEC:0001171843-25-002086:0
Canonical exit: 6 Jul 2025 (T+90)
20,000 shares@ US$1.427.9% of flowCommon StockSEC:0001171843-25-002084:0
Canonical exit: 6 Jul 2025 (T+90)
41,687 shares@ US$3.503.3% of flowCommon StockSEC:0001171843-25-000735:0
58,054 shares@ US$1.862.4% of flowCommon StockSEC:0001171843-25-000195:0
400,000 shares@ US$1.6553.2% of flowCommon StockSEC:0001171843-24-006859:0
44,782 shares@ US$1.451.4% of flowCommon StockSEC:0001171843-24-000714:0
49,198 shares@ US$1.452.0% of flowCommon StockSEC:0001171843-24-000715:0
637,500 shares@ US$1.9326.1% of flowCommon StockSEC:0001171843-24-000178:0
1,753,125 shares@ US$1.9392.7% of flowCommon StockSEC:0001171843-24-000179:0
64,415 shares@ US$1.502.7% of flowCommon StockSEC:0001171843-23-007223:0
44,025 shares@ US$1.501.4% of flowCommon StockSEC:0001171843-23-007222:0
25 of 61 declarations
About Compass Therapeutics, Inc.
Compass Therapeutics, Inc. (ticker: CMPX) is a clinical-stage biopharmaceutical company listed on the Nasdaq in the United States (United States), with headquarters in Boston, Massachusetts. The company focuses on oncology and is building a proprietary antibody-based platform designed to intervene at the intersection of angiogenesis, the immune system, and the tumor microenvironment. Its scientific premise is that anti-tumor activity can be improved by simultaneously targeting angiogenesis-driven pathways and immune-oncology mechanisms. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1738021/000117184325007005/cmpx20250930_10q.htm))
Compass was founded in 2014 and later became a public company through a reverse merger completed in 2020, giving it access to the public capital markets to fund clinical development. Since inception, management has devoted substantially all resources to research and development, intellectual property, staffing, and general corporate support. The company remains pre-commercial: it has not yet generated product revenue and continues to rely on equity financing and other capital sources to support operations. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1738021/000117184325002575/ars_042525.pdf))
Read moreShow less
The pipeline is centered on novel antibody assets, including CTX-471, a CD137 agonist antibody, CTX-8371, a PD-1 x PD-L1 bispecific antibody, and CTX-10726, a PD-1 x VEGF-A bispecific antibody. These programs are intended to enhance anti-tumor immune responses either as standalone agents or in combination regimens. From a competitive standpoint, Compass operates in a crowded and capital-intensive biotech landscape dominated by larger pharmaceutical and biotechnology groups, so differentiation depends heavily on clinical data, biomarker logic, and the ability to advance assets efficiently through development. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1738021/000117184325007005/cmpx20250930_10q.htm))
Geographically, the company is primarily U.S.-based, with its operational footprint anchored in Boston and clinical activity conducted through specialized research sites and collaborators. Recent developments have been encouraging but remain early-stage: in 2025, Compass reported that tovecimig met its primary endpoint in the randomized Phase 2/3 COMPANION-002 study in biliary tract cancer, while CTX-8371 showed confirmed partial responses in its Phase 1 program and expansion cohorts were opened or planned. Management also indicated plans to initiate a Phase 2 study for CTX-471 in 2026. Overall, CMPX offers investors a high-risk, data-driven oncology story with meaningful scientific optionality, but continued financing needs and regulatory uncertainty remain central to the investment case. ([investors.compasstherapeutics.com](https://investors.compasstherapeutics.com/news-releases/news-release-details/compass-therapeutics-reports-2025-second-quarter-financial?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
